CpG 2006 treatment prolongs the survival of syngenic BMT recipients challenged with AML cells early (day 17) after BMT.
Lethally irradiated B6 recipients were reconstituted with B6 bone marrow cells (n = 9-10 per group). Cohorts of mice, as indicated, received CpG 2006 ODNs beginning on day 12 and continuing through day 45 after BMT. C1498 cells were infused at the indicated cell doses on day 14 after BMT. A separate cohort received no C1498 cells (termed BM). CpG 2006-treated recipients of C1498 cells (105/mouse) survived longer than controls (P = .0025), whereas those that received C1498 cells (104/mouse) had a similar survival rate as compared with controls (70% versus 50%;P = .13). The decrease in tumorigenicity induced by CpG 2006 was less than 10-fold because CpG 2006-treated recipients of C1498 cells at 105 had a poorer survival than control recipients of 104 cells (P = .046). In addition, CpG 2006-treated recipients of C1498 cells at 104 had a poorer survival than control recipients of 2 × 103 cells (P = .04).
